Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICoSRA: Abatacept in Rheumatoid Arthritis
NCT02652273Phase 4Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Immunological response at 12 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02652273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652273.